1
|
Expression of Killer Immunoglobulin Receptor Genes among HIV-Infected Individuals with Non-AIDS Comorbidities. J Immunol Res 2022; 2022:1119611. [PMID: 35071606 PMCID: PMC8769865 DOI: 10.1155/2022/1119611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 12/01/2021] [Accepted: 12/17/2021] [Indexed: 11/18/2022] Open
Abstract
Combined antiretroviral therapy (cART) increased the life expectancy of people living with HIV (PLHIV) and remarkably reduced the morbidity and mortality associated with HIV infection. However, non-AIDS associated comorbidities including diabetes, hypertension, hyperlipidemia, and cardiovascular diseases (CVD) are increasingly reported among PLHIV receiving cART. Killer cell immunoglobulin receptors (KIRs) expressed on the surface of natural killer (NK) cells have been previously implicated in controlling HIV disease progression. The aim of this study is to investigate the role of KIRs in developing non-AIDS associated comorbidities among PLHIV. Demographic and behavioral data were collected from voluntary participants using a standardized questionnaire. Whole blood samples were collected for KIR genotyping. Hypertension (29.5%) and hyperlipidemia (29.5%) followed by diabetes (23.7%) and CVD (9.7%) were mainly reported among our study participants with higher rate of comorbid conditions observed among
years old. The observed KIR frequency (OF) was ≥90% for inhibitory KIR2DL1 and KIR3DL1, activating KIR2DS4 and the pseudogene KIR2DP1 among study participants. We detected significant differences in the expression of KIR3DS4 and KIR3DL1 (
) between diabetic and nondiabetic and in the expression of KIR2DL3 between hypertensive and normotensive HIV-infected individuals (
). Moreover, KIR2DL1 and KIR2DP1 were associated with significantly reduced odds of having CVD (OR 0.08; 95% CI: 0.01-0.69;
). Our study suggests the potential role of KIR in predisposition to non-AIDS comorbidities among PLHIV and underscores the need for more studies to further elucidate the role of KIRs in this population.
Collapse
|
2
|
Li Y, Wang T, Hu X, Zhang H, Bao X, Wu D, He J. Dynamic mRNA expression of donor-derived activating KIR genes and their significant effects on clinical outcome after haematopoietic stem cell transplantation. Clin Exp Immunol 2021; 205:417-428. [PMID: 34085290 DOI: 10.1111/cei.13631] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 04/28/2021] [Accepted: 05/25/2021] [Indexed: 01/24/2023] Open
Abstract
Numerous reports suggest that activating killer immunoglobulin-like receptors (aKIRs) of natural killer (NK) cells, in addition to inhibitory KIRs (iKIRs), play a prognostic role after allogeneic haematopoietic stem cell transplantation (allo-HSCT). We aimed to investigate the association between the dynamic expression of KIRs on NK cells and the outcomes, particularly regarding graft-versus-host disease (GvHD). This study retrospectively enrolled 260 pairs of donors and recipients who had undergone allo-HSCT without in-vitro T cell depletion. The mRNA transcription level of KIRs was determined by quantitative real-time polymerase chain reaction (RT-qPCR). The levels of aKIR transcripts were decreased more than those of iKIRs during the occurrence of GvHD. The transcription levels of KIR2DS2 and KIR2DS4 in the patients developing GvHD, compared with those who were at a tolerance state, showed the most significant decrease in the month at their peak transcription levels (p = 0.03, p = 0.002). Significantly decreased expression of KIR2DS1 (p = 0.02), KIR2DS3 (p = 0.04) and KIR2DS5 (p = 0.04) in the GvHD group was observed when the transcription level reached a maximum. High expression of KIR3DS1 was associated with superior overall survival (OS) (p < 0.001). The expression of KIR2DS4 in the KIR genotype Bx group decreased more during GvHD, particularly at 3M (p = 0.02). These findings suggest that KIR genes are potential post-HSCT biomarkers and dynamic changes in the KIR transcription levels can be detected to better predict the occurrence and evaluate the treatment of GvHD after transplantation.
Collapse
Affiliation(s)
- Ying Li
- Department of Haematology, Jiangsu Institute of Haematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
| | - Tian Wang
- HLA Laboratory of Jiangsu Institute of Haematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
| | - Xing Hu
- HLA Laboratory of Jiangsu Institute of Haematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
| | - Huanhuan Zhang
- HLA Laboratory of Jiangsu Institute of Haematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
| | - Xiaojing Bao
- HLA Laboratory of Jiangsu Institute of Haematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
| | - Depei Wu
- Department of Haematology, Jiangsu Institute of Haematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
| | - Jun He
- HLA Laboratory of Jiangsu Institute of Haematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China
| |
Collapse
|
3
|
He M, Zheng ZZ, He QQ, Li DY, Liao KZ, An L, Weng Q, Wang NJ, Wang LP, Sun Q, Wang J, Xiao PL, Du KM, Jiang M. Distribution of killer cell immunoglobulin-like receptor (KIR) genes in a large, multi-centre cohort of Chinese donors. Ann Hum Biol 2021; 48:133-141. [PMID: 34097546 DOI: 10.1080/03014460.2021.1913223] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND The killer cell immunoglobulin-like receptor (KIR), which mediates the killing function of NK cells, is an attractive candidate for adoptive cellular therapy. The ethnic distribution for China provides a unique opportunity to investigate KIR gene distribution. AIM The aim of this study was to explore the relationship between population history and the rapidly evolving KIR genetic diversity. SUBJECTS AND METHODS 8050 Chinese donors from 184 hospitals were included to analyse frequency, haplotype, and B-content data of 16 KIR genes, by PCR-SSP for KIR genotyping. RESULTS KIR gene carrier frequencies were found similar to those observed in other studies on Han, but different from Thais, Japanese, Africans, and populations of West Eurasian ancestry. High-frequency KIR genotype profiles found in the present population were consistent with other studies on Han populations but different from those conducted on other cohorts. The majority of our cohort carried group A KIR gene motifs. Additionally, populations with similar geographic locations in China were shown clustered together, while Hainan and Xinjiang provinces were slightly separated from these. CONCLUSION The distribution of KIR genes varies by geographic region, and different ethnic groups may be a confounding factor of KIR diversity.
Collapse
Affiliation(s)
- Min He
- Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.,Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China
| | | | - Qing-Qing He
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Dai-Yang Li
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Kuan-Zhen Liao
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Lin An
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Qi Weng
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Ning-Juan Wang
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Li-Ping Wang
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Qin Sun
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Jian Wang
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Pei-Li Xiao
- Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China
| | - Ke-Ming Du
- Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China
| | - Ming Jiang
- Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.,Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China
| |
Collapse
|